Search hospitals > Minnesota > Minneapolis

Mercy Hospital

Claim this profile
Minneapolis, Minnesota 55433
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
393 reported clinical trials
14 medical researchers
Photo of Mercy Hospital in MinneapolisPhoto of Mercy Hospital in MinneapolisPhoto of Mercy Hospital in Minneapolis

Summary

Mercy Hospital is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Mercy Hospital is involved with conducting 393 clinical trials across 549 conditions. There are 14 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.

Area of expertise

1Cancer
Global Leader
Mercy Hospital has run 171 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Mercy Hospital has run 105 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Mercy Hospital

Breast Cancer
Cancer
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Prostate Cancer
Esophageal Carcinoma
Lung Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Esophageal Cancer
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Mercy Hospital?
Mercy Hospital is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Adenocarcinoma and other specialties. Mercy Hospital is involved with conducting 393 clinical trials across 549 conditions. There are 14 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Mercy Hospital located?
**Mercy Hospital Location and Directions:** - **Address:** 4050 Coon Rapids Blvd, Coon Rapids, MN 55433. - **Directions:** From Interstate 694, take the Hwy 252 North exit. Follow Hwy 252 to Interstate 610 East, then continue on Hwy 10 to reach the hospital.
Who should I call to ask about financial aid or insurance network?
For Mercy Hospital's financial assistance, please call 410-951-1700. For general billing and insurance inquiries, contact the customer service team at 855-420-7900.
What insurance does Mercy Hospital accept?
Mercy Hospital accepts a wide range of insurance plans such as MercyCare, Aetna, Blue Cross Blue Shield, ChoiceCare, Humana, Health Alliance, and Meridian among others. It's important to verify with your insurance provider as accepted plans can vary by hospital location. Note that some insurance plans may be considered out-of-network, making patients responsible for total billed charges.
What awards or recognition has Mercy Hospital received?
Mercy Hospital in Minneapolis, Minnesota, is renowned for its commitment to patient safety, quality care, and research. It has been recognized by the Minnesota Department of Health for excellence in patient safety and named among the 50 Top Cardiovascular Hospitals®. The hospital holds accreditation from The Joint Commission and certification as a Primary Stroke Center by DNV, with Mercy Research leading in community health system-based research across multiple therapeutic areas.